MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma

Leukemia. 2014 Oct;28(10):2104-6. doi: 10.1038/leu.2014.184. Epub 2014 Jun 6.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Female
  • Gene Expression Profiling
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / genetics*
  • Lymphoma, Large B-Cell, Diffuse / mortality
  • Lymphoma, Large B-Cell, Diffuse / therapy
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Mutation*
  • Myeloid Differentiation Factor 88 / genetics*
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Treatment Outcome

Substances

  • MYD88 protein, human
  • Myeloid Differentiation Factor 88